AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6414387 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 63
Study 6414387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate (Myocrisin)
Number of subjects: 63
Study 6414387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 31561331 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrospun PEEU fiber meshes
Number of subjects: 0
Study 31561331 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fibers
Number of subjects: 0
Study 31561331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber mesh architecture
Number of subjects: 0
Study 28933609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task training program (n=8)
Number of subjects: 20
Study 28933609 — intervention group
Group type: COMPARATOR
Intervention: Single task training program (n=6)
Number of subjects: 20
Study 25598453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical pressure-attenuation balloon
Number of subjects: 63
Study 25598453 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 63
Study 24346811 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release paliperidone (paliperidone ER) 6 mg
Number of subjects: 25
Study 24346811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral risperidone (mean dose: 4.0 mg)
Number of subjects: 25
Study 24346811 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from oral risperidone to paliperidone ER
Number of subjects: 25
Study 21701846 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at preferred stride frequency (PSF)
Number of subjects: 12
Study 21701846 — intervention group
Group type: COMPARATOR
Intervention: Walking at stride frequencies other than PSF
Number of subjects: 12
Study 21701846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower stride frequencies
Number of subjects: 12
Study 21701846 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at PSF
Number of subjects: 12
Study 21121492 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (CBT) intervention program, conducted over four consecutive 1.5-hour weekly sessions.
Number of subjects: 26
Study 21121492 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 26
Study 18159576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 60
Study 18159576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol-metamizol
Number of subjects: 60
Study 18159576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol-lornoxicam
Number of subjects: 60
Study 15896432 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/GLN/ARG
Number of subjects: 40
Study 15896432 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrogen and calorie balanced mixture of alanine, glutamic acid, glycine, and serine)
Number of subjects: 40
Study 12387694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 0
Study 9594939 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day
Number of subjects: 372
Study 9594939 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200 mg/day
Number of subjects: 372
Study 7751526 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine and anti-inflammatory medicines timed to the day-night temporal pattern in symptom manifestation and intensity.
Number of subjects: 0
Study 7751526 — intervention group
Group type: COMPARATOR
Intervention: Traditional equal-interval, equal-dose medication schedules.
Number of subjects: 0
Study 2693113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 11
Study 2693113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 401194 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg bolus of methylprednisolone
Number of subjects: 0
Study 401194 — intervention group
Group type: COMPARATOR
Intervention: 3 mg/kg bolus of methylprednisolone
Number of subjects: 0
Study 30975599 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreatoduodenectomy (LPD)
Number of subjects: 38
Study 30975599 — intervention group
Group type: COMPARATOR
Intervention: Open pancreatoduodenectomy (OPD)
Number of subjects: 38
Study 30975599 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Clavien-Dindo ≥ III complications
Number of subjects: 38
Study 30975599 — intervention group
Group type: COMPARATOR
Intervention: Patients without Clavien-Dindo ≥ III complications
Number of subjects: 38
Study 30975599 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with POPF grade B/C
Number of subjects: 38
Study 30975599 — intervention group
Group type: COMPARATOR
Intervention: Patients without POPF grade B/C
Number of subjects: 38
Study 30975599 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with POPF grade B/C after LPD
Number of subjects: 38
Study 30975599 — intervention group
Group type: COMPARATOR
Intervention: Patients with POPF grade B/C after OPD
Number of subjects: 38
Study 28327526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ser‐Se‐Ly association (n = 45)
Number of subjects: 90
Study 28327526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 45)
Number of subjects: 90
Study 25972575 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU/month)
Number of subjects: 275
Study 25972575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 24331203 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Family Education (PFE)
Number of subjects: 117
Study 24331203 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Partnership Intervention (FPI)
Number of subjects: 117
Study 24331203 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 117
Study 24331203 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Adherence (MA)
Number of subjects: 117
Study 21804511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 60
Study 21804511 — intervention group
Group type: COMPARATOR
Intervention: Control (no Dexamethasone)
Number of subjects: 60
Study 19907850 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold-alloy post-core-crowns
Number of subjects: 289
Study 19907850 — intervention group
Group type: COMPARATOR
Intervention: Nickel-chromium-alloy post-core-crowns
Number of subjects: 289
Study 16681474 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hysterectomy (laparoscopic assisted vaginal hysterectomy, N = 32)
Number of subjects: 63
Study 16681474 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy (supracervical laparoscopic hysterectomy, N = 31)
Number of subjects: 63
Study 16681474 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hysterectomy (N = 32)
Number of subjects: 63
Study 16681474 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy (N = 31)
Number of subjects: 63
Study 16681474 — intervention group
Group type: COMPARATOR
Intervention: Minor gynecological surgery (SURG‐CON, N = 30)
Number of subjects: 63
Study 16681474 — intervention group
Group type: COMPARATOR
Intervention: Healthy nonsurgical controls (NORM‐CON, N = 40)
Number of subjects: 63
Study 15484710 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance athletes
Number of subjects: 158
Study 15484710 — intervention group
Group type: EXPERIMENTAL
Intervention: Power athletes
Number of subjects: 158
Study 15484710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball game players
Number of subjects: 158
Study 15484710 — intervention group
Group type: COMPARATOR
Intervention: Non-athletic subjects
Number of subjects: 158
Study 11739353 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional bonesetters (TBS) treatment
Number of subjects: 49
Study 11739353 — intervention group
Group type: COMPARATOR
Intervention: Orthodox treatment in hospital
Number of subjects: 49
Study 9233719 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 69
Study 9233719 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 69
Study 8497353 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrapartum electronic fetal heart rate monitoring (EFM)
Number of subjects: 1428
Study 8497353 — intervention group
Group type: COMPARATOR
Intervention: Intermittent auscultation
Number of subjects: 1428
Study 2828818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2828818 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg naloxone
Number of subjects: 9
Study 2828818 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg naloxone
Number of subjects: 9
Study 31576625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led education and follow-up service (PEFS)
Number of subjects: 152
Study 31576625 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 152
Study 28591764 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo (P)
Number of subjects: 100
Study 28591764 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplement (W)
Number of subjects: 100
Study 28591764 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home rehabilitation + placebo (R+P)
Number of subjects: 100
Study 28591764 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation + whey protein (R+W)
Number of subjects: 100
Study 28591764 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 100
Study 26008820 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet with soluble milk proteins (PRO HP)
Number of subjects: 31
Study 26008820 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet with caseins (CAS HP)
Number of subjects: 31
Study 26008820 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate-protein diet with soluble milk proteins (PRO AP)
Number of subjects: 31
Study 26008820 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding with soluble milk proteins (PRO)
Number of subjects: 31
Study 26008820 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding with caseins (CAS)
Number of subjects: 31
Study 25399618 — intervention group
Group type: EXPERIMENTAL
Intervention: New combination of retinoids and depigmenting agents
Number of subjects: 30
Study 25399618 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 30
Study 22545614 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction-based task sets
Number of subjects: 0
Study 22545614 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of instructions in declarative working memory
Number of subjects: 0
Study 20354468 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor therapy (home program and 3 outpatient sessions)
Number of subjects: 107
Study 20354468 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy (home program focusing on pain contingent training of back, abdominal, and leg muscle functional strength and endurance, stretching, and cardiovascular fitness)
Number of subjects: 107
Study 20354468 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor therapy
Number of subjects: 107
Study 18845961 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 1440 UI of hepatitis A vaccine (HAVRIX) at weeks 0, 4, and 24
Number of subjects: 95
Study 18845961 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of hepatitis A vaccine 24 weeks apart
Number of subjects: 95
Study 16682791 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol for 3 months
Number of subjects: 9
Study 16682791 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 9
Study 14642682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg/day)
Number of subjects: 60
Study 14642682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10868768 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-site interventions for smoking cessation
Number of subjects: 2106
Study 8977984 — intervention group
Group type: EXPERIMENTAL
Intervention: 1M depot formulation
Number of subjects: 237
Study 8977984 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M depot formulation
Number of subjects: 237
Study 1608405 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin alone
Number of subjects: 403
Study 1608405 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 403
Study 1608405 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Heparin and Aspirin)
Number of subjects: 403
Study 1608405 — intervention group
Group type: COMPARATOR
Intervention: Neither treatment (placebo)
Number of subjects: 403
Study 6204148 — intervention group
Group type: EXPERIMENTAL
Intervention: Na+‐K+‐Mg2+ salt (replacing 35 or 55% of NaCl) for 3-5 weeks in hospitalized patients and 6 months in outpatients
Number of subjects: 126
Study 6204148 — intervention group
Group type: EXPERIMENTAL
Intervention: Na+‐K+‐Mg2+ salt
Number of subjects: 126
Study 31416744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based psycho-education group programme
Number of subjects: 180
Study 31416744 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education group
Number of subjects: 180
Study 31416744 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual group
Number of subjects: 180
Study 28699770 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation consisting of a physical exercise program and psycho-educational consultations
Number of subjects: 210
Study 28699770 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study 28699770 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation
Number of subjects: 210
Study 26361994 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (18.75 mg/day)
Number of subjects: 13
Study 26361994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 26361994 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 13
Study 25303140 — intervention group
Group type: EXPERIMENTAL
Intervention: TST (Tuberculin Skin Test)
Number of subjects: 1728
Study 25303140 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB-Gold in-tube test (ELISA)
Number of subjects: 1728
Study 25303140 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT.TB test (enzyme-linked immunospot)
Number of subjects: 1728
Study 25303140 — intervention group
Group type: EXPERIMENTAL
Intervention: TST
Number of subjects: 1728
Study 25303140 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection with positive TST
Number of subjects: 1728
Study 25303140 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection with positive ELISA
Number of subjects: 1728
Study 25303140 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection with positive enzyme-linked immunospot result
Number of subjects: 1728
Study 25303140 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive chemotherapy
Number of subjects: 1728
Study 22075016 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 160
Study 22075016 — intervention group
Group type: COMPARATOR
Intervention: LMA Fastrach
Number of subjects: 160
Study 19809363 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg once daily for 4 weeks, then randomized to valsartan 160, 320, or 640 mg/day for 26 weeks
Number of subjects: 110
Study 19809363 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 or 640 mg/day
Number of subjects: 110
Study 19809363 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg/day
Number of subjects: 110
Study 18028060 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid
Number of subjects: 0
Study 18028060 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer
Number of subjects: 0
Study 18028060 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX GP (glass ionomer cement)
Number of subjects: 0
Study 18028060 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond 2 (resin-based adhesive)
Number of subjects: 0
Study 18028060 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (resin-based adhesive)
Number of subjects: 0
Study 16197283 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast ForWord (FFW) intervention, home-based therapy for 6 weeks
Number of subjects: 77
Study 16197283 — intervention group
Group type: COMPARATOR
Intervention: Commercially available computer-based activities (control for computer games exposure)
Number of subjects: 77
Study 16197283 — intervention group
Group type: COMPARATOR
Intervention: No additional study intervention
Number of subjects: 77
Study 11834877 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilazep dihydrochloride (300 mg/day, n = 20)
Number of subjects: 60
Study 11834877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 60
Study 10051861 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel strike slips
Number of subjects: 65
Study 10051861 — intervention group
Group type: EXPERIMENTAL
Intervention: Midstance slips
Number of subjects: 65
Study 10051861 — intervention group
Group type: COMPARATOR
Intervention: Older adults' responses to heel strike slips
Number of subjects: 65
Study 7729995 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B tympanogram
Number of subjects: 4214
Study 1718721 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable rotation amplitude (serial 4 degrees versus serial 10 degrees)
Number of subjects: 0
Study 1718721 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable rotation amplitude (random mixture of 4 degrees and 10 degrees)
Number of subjects: 0
Study 1718721 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal subjects exposed to 2 perturbation amplitudes
Number of subjects: 0
Study 7258754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretylium tosylate (10 mg/kg)
Number of subjects: 59
Study 7258754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 59
Study 30895912 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized visual patterns (10% increments of checkerboard and randomized line orientation)
Number of subjects: 0
Study 30895912 — intervention group
Group type: COMPARATOR
Intervention: Ordered visual patterns (structured checkerboard and square array of vertical line segments)
Number of subjects: 0
Study 30895912 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference results for openness and neuroticism
Number of subjects: 0
Study 29996841 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable tacks
Number of subjects: 0
Study 29996841 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable tacks
Number of subjects: 0
Study 26786042 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg three times daily for 3 days)
Number of subjects: 30
Study 26786042 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 30
Study 24760356 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group‐based HIV and STI prevention intervention
Number of subjects: 40
Study 21542121 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing DAPT at 30 days (n = 4249)
Number of subjects: 4259
Study 21542121 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing DAPT at 6 months (n = 2654)
Number of subjects: 4259
Study 21542121 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing DAPT
Number of subjects: 4259
Study 21136333 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day glucocorticoid treatment followed by 9 days of placebo
Number of subjects: 0
Study 21136333 — intervention group
Group type: COMPARATOR
Intervention: 14-day course of systemic glucocorticoids (40 mg of prednisone-equivalent daily)
Number of subjects: 0
Study 17645428 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM)
Number of subjects: 388
Study 17645428 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 388
Study 14706762 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein containing 99 mg naturally occurring isoflavones
Number of subjects: 202
Study 14706762 — intervention group
Group type: COMPARATOR
Intervention: Placebo (milk protein)
Number of subjects: 202
Study 11871584 — intervention group
Group type: EXPERIMENTAL
Intervention: Assured Treatment (AT)
Number of subjects: 59
Study 11871584 — intervention group
Group type: EXPERIMENTAL
Intervention: Disbeliever Treatment (DT)
Number of subjects: 59
Study 11871584 — intervention group
Group type: COMPARATOR
Intervention: Non-Targeted Treatment (NT)
Number of subjects: 59
Study 9926278 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 2‐8 mg/day orally for 8‐12 weeks
Number of subjects: 10
Study 7819982 — intervention group
Group type: EXPERIMENTAL
Intervention: DICE therapy
Number of subjects: 44
Study 7819982 — intervention group
Group type: EXPERIMENTAL
Intervention: Red dice therapy
Number of subjects: 44
Study 7819982 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluding red dice trials and poor methodological quality trials
Number of subjects: 44
Study 7819982 — intervention group
Group type: EXPERIMENTAL
Intervention: Published trials
Number of subjects: 44
Study 7819982 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with familiar trialists
Number of subjects: 44
Study 3061859 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 78
Study 3061859 — intervention group
Group type: COMPARATOR
Intervention: 800 mg cimetidine
Number of subjects: 78
Study 31174454 — intervention group
Group type: EXPERIMENTAL
Intervention: Process and outcome feedback
Number of subjects: 197
Study 31174454 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 197
Study 29447778 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day atorvastatin
Number of subjects: 150
Study 29447778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 28070889 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided parent-delivered cognitive behaviour therapy (CBT)
Number of subjects: 57
Study 26047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent presence during speech preparation (N=39)
Number of subjects: 75
Study 26047719 — intervention group
Group type: COMPARATOR
Intervention: Stranger presence during speech preparation
Number of subjects: 75
Study 26047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent presence during speech preparation
Number of subjects: 75